PMS-DIGOXIN 0.125 MG — DIN 02245427
DIGOXIN : 0.125 MG · PHARMASCIENCE INC · TABLET · wholesale supply in Canada
Health Canada status: CANCELLED POST MARKET
What is PMS-DIGOXIN?
PMS-DIGOXIN 0.125 MG contains DIGOXIN : 0.125 MG. It is listed in the Health Canada Drug Product Database under DIN 02245427, held by PHARMASCIENCE INC, supplied as TABLET for ORAL administration. Health Canada currently lists it as cancelled post market, status dated 28-Oct-2016. This Drug Identification Number is no longer authorized for sale in Canada, so Nexara does not supply it. The record is kept here because buyers still meet the number on old formularies, purchase orders and tender documents; Nexara can help identify an authorized alternative.
What is PMS-DIGOXIN used for?
Treatment of mild to moderate congestive heart failure and control of ventricular response rate in patients with chronic atrial fibrillation.
Authorized indication as written in the Health Canada product monograph. For healthcare professionals and licensed purchasers; this is not medical advice.
How much does Digoxin cost around the world?
Digoxin is listed on 9 of the national price registers Nexara ingests. Each country publishes on a different basis, so those figures are not comparable with one another — or with a Canadian wholesale price.
What a market publishes matters more than the number it publishes. Australia publishes a ex-manufacturer; Bahrain publishes a retail (max); Greece publishes a producer price (ex-factory). Comparing an ex-factory ceiling against a pharmacy public price tells you nothing about either, and comparing either against a Canadian landed cost tells you less.
| Market | Price basis published there | Brands | Packs listed | Range |
|---|---|---|---|---|
| United States | acquisition | 4 | 33 | USD███.██ |
| Saudi Arabia | public | 7 | 12 | SAR███.██ |
| South Africa | single exit price | 4 | 11 | ZAR███.██ |
| Australia | ex-manufacturer | 4 | 5 | AUD███.██ |
| United Arab Emirates | public | 4 | 4 | AED███.██ |
| Greece | producer price (ex-factory) | 2 | 2 | EUR███.██ |
| Romania | max producer price | 2 | 2 | RON███.██ |
| Bahrain | retail (max) | 1 | 1 | BHD███.██ |
| Hungary | producer price (ex-factory) | 1 | 1 | HUF███.██ |
71 pack listings across 29 brand entries and 7 price bases, refreshed 08 Sep 2026. Ranges span every Digoxin pack in that market, so a high figure is usually a larger pack rather than the same product.
This table is a regulatory record of where the molecule is listed. The DIN on this page is no longer authorized for sale in Canada, so Nexara does not quote it — see the alternatives above.
Is there a generic Digoxin in Canada, and who makes it?
Every market authorization holder with a Canadian DIN for this molecule, and how many of their listings Health Canada currently shows as marketed.
8 holders have a Canadian DIN containing Digoxin, across 32 DINs, of which 8 are currently marketed. Marketed count is the number that matters: an approval that is not marketed cannot be bought.
| Market authorization holder | DINs | Marketed | Brand names | Position |
|---|---|---|---|---|
| PHARMASCIENCE INC | 14 | 3 | LANOXIN, PMS-DIGOXIN | Sourceable in Canada |
| JAMP PHARMA CORPORATION | 3 | 2 | JAMP DIGOXIN | Sourceable in Canada |
| AURO PHARMA INC | 2 | 2 | AURO-DIGOXIN | Sourceable in Canada |
| SANDOZ CANADA INCORPORATED | 2 | 1 | DIGOXIN INJECTION C.S.D., PEDIATRIC DIGOXIN INJECTION C.S.D. | Sourceable in Canada |
| GLAXO WELLCOME INC. | 6 | 0 | LANOXIN ELX 0.05MG/ML PEDIATRIC, LANOXIN INJ 0.05MG/ML PEDIATRIC, LANOXIN INJ 0.25MG/ML, LANOXIN TAB 0.0625MG, LANOXIN TAB 0.125MG, +1 more | No marketed DIN |
| APOTEX INC | 3 | 0 | APO-DIGOXIN | No marketed DIN |
| DYMOND DRUGS LTD. | 1 | 0 | DIGITALIS POWDERED TABLETS CSD 1GR | No marketed DIN |
| NOVOPHARM LIMITED | 1 | 0 | NOVO-DIGOXIN TAB 0.25MG | No marketed DIN |
Health Canada’s Drug Product Database does not flag which listing is the originator and which are subsequent-entry products, so Nexara does not label them here. Interchangeability is determined provincially, not federally — confirm for your province before a formulary switch. Nexara can confirm which of these is actually obtainable, and on what lead time, per order.
How is it supplied and stored?
Pack configuration, storage class and the handling constraints that drive cold-chain planning. One DIN can cover more than one pack size, and the pack — not the DIN — is what gets priced, shipped and invoiced.
| Strength on the label | 0.125 MG |
|---|---|
| Dosage form | TABLET |
| Route | ORAL |
| Pack configuration (monograph) | Not explicitly detailed in provided text (Tablets 0.0625 mg, 0.125 mg, 0.25 mg). |
| Storage | Not explicitly detailed in provided text (Standard reference is usually 15-30°C). |
Pack detail is kept as a regulatory record. This DIN is no longer authorized for sale in Canada, so Nexara does not quote this pack.
Substance and classification
| Active substance | Digoxin |
|---|---|
| ATC code | C01AA05 |
| AHFS class | 24:04.08 |
| Biosimilar biologic | No |
Health Canada record and identifiers
The regulatory facts straight from the Drug Product Database, plus every identifier form Nexara accepts on a purchase order. A DIN written without its leading zeros is the commonest reason an order line fails to match.
| DIN (8-digit, as used in ordering) | 02245427 |
|---|---|
| DIN (unpadded, as printed on some documents) | 2245427 |
| Brand name | PMS-DIGOXIN |
| Generic / active ingredient | DIGOXIN : 0.125 MG |
| Market authorization holder | PHARMASCIENCE INC |
| Health Canada schedule | Prescription |
| ATC code | C01AA05 |
| ATC anatomical main group | C — Cardiovascular system |
| ATC therapeutic subgroup | C01AA |
| Current status | CANCELLED POST MARKET |
| Status date | 28-Oct-2016 |
| Original market date | 2006-06-21 00:00:00 |
| Status source | Live Health Canada DPD sync |
Verify on the primary sources
How is it administered?
Individualize based on age, body weight, and renal function. Dosage must be titrated. Bioavailability differences between forms must be considered when switching.
Included because it drives pack selection and wastage. Consult the monograph.
Contraindications
Ventricular fibrillation; hypersensitivity to digoxin or other digitalis glycosides.
Warnings and precautions
Narrow therapeutic range. Toxicity risk increased by hypokalemia, hypomagnesemia, hypercalcemia, and renal impairment. Not for obesity treatment. Use caution in acute MI.
What can be used instead?
Alternatives on every axis a buyer actually considers — the same molecule in another presentation, the same class, an adjacent class, or a fixed-dose combination. Every row is led by the marketed DIN count, because that is what can be bought this week.
1 · Same molecule, other Canadian presentations
8 of 32 Canadian DINs for this molecule are currently marketed. Marketed products are listed first.
| Product | Strength | Form | Holder | Health Canada status | DIN |
|---|---|---|---|---|---|
| AURO-DIGOXIN | 0.0625 MG | TABLET | AURO PHARMA INC | MARKETED | 02554399 |
| AURO-DIGOXIN | 0.125 MG | TABLET | AURO PHARMA INC | MARKETED | 02554402 |
| DIGOXIN INJECTION C.S.D. | 0.5 MG / 2 ML | LIQUID | SANDOZ CANADA INCORPORATED | MARKETED | 02048264 |
| JAMP DIGOXIN | 0.125 MG | TABLET | JAMP PHARMA CORPORATION | MARKETED | 02498510 |
| JAMP DIGOXIN | 0.0625 MG | TABLET | JAMP PHARMA CORPORATION | MARKETED | 02498502 |
| PMS-DIGOXIN | 0.05 MG | SOLUTION | PHARMASCIENCE INC | MARKETED | 02242320 |
| PMS-DIGOXIN | 0.125 MG | TABLET | PHARMASCIENCE INC | MARKETED | 02335719 |
| PMS-DIGOXIN | 0.0625 MG | TABLET | PHARMASCIENCE INC | MARKETED | 02335700 |
| APO-DIGOXIN | 0.25 MG | TABLET | APOTEX INC | DORMANT | 02281201 |
| APO-DIGOXIN | 0.0625 MG | TABLET | APOTEX INC | DORMANT | 02281236 |
2 · Same class — other molecules in ATC C01AA
| Molecule | Canadian brands | DINs | Marketed | Sourceable |
|---|---|---|---|---|
| Digoxin | APO-DIGOXIN · AURO-DIGOXIN · DIGITALIS POWDERED TABLETS CSD 1GR · DIGOXIN INJECTION C.S.D. · +11 more | 32 | 8 | Yes |
| Digitoxin | DIGITALINE WELCKER TAB 0.1MG | 1 | 0 | Not in Canada |
A molecule with zero marketed DINs cannot be sourced domestically, however many approvals it holds — if one of these sits on a formulary or in an older protocol, that is the line to check.
Not clinical advice. These tables describe what can be supplied in Canada, not what should be prescribed. Substitution within or across classes is a prescriber and pharmacist decision, and interchangeability is determined provincially.
What else is PMS-DIGOXIN called?
The same molecule, Digoxin, is registered under other names elsewhere. Buyers and prescribers searching from outside Canada — or working from a foreign prescription or tender document — often know it by one of these:
| Name | Script | Registered in |
|---|---|---|
| Lanoxin | Latin | Australia, Bahrain, South Africa |
| Lanoxin PG | Latin | South Africa |
| Purgoxin | Latin | South Africa |
| Lanoxin-PG | Latin | Australia |
| Lanoxin* | Latin | United Arab Emirates |
| Sigmaxin | Latin | Australia |
| Sigmaxin-PG | Latin | Australia |
Names are taken from national medicine registers and published price lists. A product registered abroad is not authorized for sale in Canada unless it holds its own DIN; import is possible only through the routes Health Canada permits.
Can this still be bought in Canada?
No. This Drug Identification Number is cancelled post market in Health Canada's Drug Product Database, so the product is no longer authorized for sale in Canada and Nexara does not supply it. This page is kept as a regulatory record.
If you are looking for a current equivalent, the alternatives above list every product sharing this therapeutic class, with the marketed ones first. Ask us to source an alternative
Ordering questions
Who can buy this from Nexara?
Licensed entities only. Nexara holds Health Canada establishment licence DEL 3-002896-A and ships only to a licensed address. Patients and unlicensed buyers are routed to a partner pharmacy.
Is there a minimum order?
Yes, set per product line and per pack multiple rather than on the order total, so you are never asked to buy a part-pack. The minimum for this line is confirmed with your quote.
What is the lead time?
Confirmed per order at quotation, and it depends on current stock position and whether the product is in shortage.
Why is there no price on this page?
Nexara quotes a delivered Canadian price per order, against a verified licence. Foreign list prices are published on incompatible bases and are not a guide to what any buyer can obtain here, so this page shows which markets list the molecule and on what basis, and nothing more.
Can Nexara supply this for a clinical trial?
Yes — comparator and background-therapy supply, including sourcing from other markets where a Canadian pack will not satisfy the protocol. Clinical trial supply.